Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
Lin Lin, Jinquan Cai, Zixiao Tan, Xiangqi Meng, Ruiyan Li, Yang Li, Chuanlu Jiang
Cancer Res Treat. 2021;53(2):367-377.   Published online 2020 Oct 13     DOI: https://doi.org/10.4143/crt.2020.506
Citations to this article as recorded by Crossref logo
Oncometabolites as Regulators of DNA Damage Response and Repair
Susan E. Gueble, Ranjit S. Bindra
Seminars in Radiation Oncology.2022; 32(1): 82.     CrossRef
Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma
Liesbeth Everix, Shankari Nair, Cathryn H. S. Driver, Ingeborg Goethals, Mike M. Sathekge, Thomas Ebenhan, Charlot Vandevoorde, Julie Bolcaen
Cancers.2022; 14(7): 1821.     CrossRef
Chk1/2 inhibitor AZD7762 enhances the susceptibility of IDH-mutant brain cancer cells to temozolomide
Erkin Ozgiray, Fatma Sogutlu, Cigir Biray Avci
Medical Oncology.2022;[Epub]     CrossRef
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
Xueyuan Sun, Sevin Turcan
Cells.2021; 10(5): 1225.     CrossRef
From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy
Emanuela Di Gregorio, Gianmaria Miolo, Asia Saorin, Agostino Steffan, Giuseppe Corona
International Journal of Molecular Sciences.2021; 22(11): 5574.     CrossRef
The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ)
Weilu Kuang, Wuzhong Jiang, Yinyun Chen, Yifu Tian, Zhengzheng Liu
Cancer Biology & Therapy.2021; 22(5-6): 392.     CrossRef
Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53–PUMA Apoptosis Pathway
Hong-Chieh Tsai, Kuo-Chen Wei, Pin-Yuan Chen, Chiung-Yin Huang, Ko-Ting Chen, Ya-Jui Lin, Hsiao-Wei Cheng, Yi-Rou Chen, Hsiang-Tsui Wang
Frontiers in Oncology.2021;[Epub]     CrossRef